Xu, Yiyang
Yang, Zhiyuan
Horan, Lucas H.
Zhang, Pengbo
Liu, Lianxing
Zimdahl, Bryan
Green, Shon
Lu, Jingwei
Morales, Javier F.
Barrett, David M.
Grupp, Stephan A.
Chan, Vivien W. http://orcid.org/0000-0001-7663-1130
Liu, Hong
Liu, Cheng
Article History
Received: 1 August 2018
Revised: 27 September 2018
Accepted: 28 September 2018
First Online: 20 November 2018
Conflict of interest
: Y.X., Z.Y., L.H.H., P.Z., L.L., B.Z., S.G., J.L., J.F.M., V.W.C., H.L., and C.L. are employees of and have equity ownership and/or stock options in Eureka Therapeutics, Inc. S.A.G. is a scientific advisor to Eureka Therapeutics with stock options in the company. D.M.B. is a consultant to Eureka Therapeutics. Other associations: S.A.G. has received research and/or clinical trial support from Novartis, Servier and Kite. He consults for, has participated in ad boards, or serves on study steering committees or scientific advisory boards for the following companies: Novartis, Adaptimmune, TCR2, Juno, GlaxoSmithKline, Cellectis, Vertex, Roche and Janssen. He is listed on a patent related to toxicity management in cell therapy managed by University of Pennsylvania and CHOP policies.